Navigation Links
GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
Date:10/29/2010

tional funding to complete all of our studies and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company's cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans, including achievement of development and commercialization milestone payments and sales royalties under our collaboration with GlaxoSmithKline . In addition, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2009. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

GSK's cautionary statement regarding forward-looking statementsUnder the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2009.Registered in England & Wales:

No. 3888792Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GSFOLD –G


'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... LAKE, N.J. and STAMFORD, Conn. ... U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue ... a worldwide collaboration agreement for the development and commercialization ... dual orexin receptor antagonist entering Phase III clinical development ... the terms of the agreement, Eisai and Purdue Pharma ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited (ASX:BNO, ... development of innovative therapeutics for the treatment of diseases ... announced that its BNC101 IND submission has passed review ... plans to initiate a Phase 1 clinical trial in ... metastatic pancreatic cancer prior to 31 December 2015. ...
(Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/wmn42n/prescription_pain ) has ... Drugs - Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ ... Opportunities: 2015 - 2020 Analysis and Forecasts" ... is defined as an unpleasant sensory and emotional ... At some point, everyone experiences pain. Pain may ...
Breaking Medicine Technology:Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 2Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 3
... announced that the U.S. Food and Drug Administration ... treatment of adult patients with glioblastoma multiforme (GBM) ...  The portable, wearable device delivers an anti-mitotic, anti-cancer ... The NovoTTF is a novel, first-in-class treatment option ...
... 2011 StelKast is proud to announce the ... Acetabular Liners. EXp™, a blend of antioxidant and ... consulting support of Steven Kurtz, Ph.D. and Exponent, ... clearance for large diameter cobalt-chrome femoral heads and ...
Cached Medicine Technology:FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors 2FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors 3FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors 4A Better Acetabular Solution from StelKast ... Naturally 2
(Date:8/31/2015)... ... August 31, 2015 , ... With the FCPX LUT Soft pack from Pixel Film ... a Lookup Table that contains a mathematical formula for modifying an image. The LUT changes ... 60 soft CUBE LUT files. , FCPX LUT Soft requires Final Cut Pro X ...
(Date:8/31/2015)... ... 31, 2015 , ... How can healthcare meet the challenge ... , In a commentary for The American Journal of Managed Care , ... efficacy,” which would bind parties together in agreements to intervene at the earliest ...
(Date:8/31/2015)... CA (PRWEB) , ... August 31, 2015 , ... ... print and digital marketing communications company announced today that it has officially launched ... DP President, the new website and brand refresh are more closely aligned with ...
(Date:8/31/2015)... ... , ... The dental implant and prosthetic market in the U.S. is projected ... Press Room ) More than 30 million Americans are missing all their teeth ... for dental implants, the National Association of Dental Laboratories (NADL) created the “What’s In ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... franchise business with a ribbon-cutting ceremony on Aug. 26, generously hosted by the ... booking inspection appointments via AdvantaClean’s National Call Center and website since Aug. 17. ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios, FCPX Plugin Developer, Releases FCPX LUT Soft 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Dental Association Raises Awareness as Implant Industry Grows 2Health News:Dental Association Raises Awareness as Implant Industry Grows 3Health News:Dental Association Raises Awareness as Implant Industry Grows 4Health News:Ribbon Cutting Launches AdvantaClean of Madison County 2
... been stepped up in China, the official Xinhua news agency ... much dreaded Avian influenza or “bird flu” caused by H5N1 ... ago. China has accelerated efforts to monitor bird flu status ... at large and officials have been urged to keep an ...
... evidence supporting the view that ancient men did perform brain ... claim to have unearthed a skull which appears to date ... The skull was found during excavations that were being carried ... ,Georgi Nehrizov informed the press that the skull, which they ...
... the total spending on Medicaid has shown its slowest pace ... a better economy// that has held down new enrollments, cost-containment ... according to a new survey. ,Medicaid is the state-federal health ... of 2.8 percent in fiscal 2006, according to the survey ...
... authority in organ transplantation and an eminent personality delivered ... (CMCH) Ludhiana recently. ,Speaking at the gathering he ... information about organ donation in India and how exactly ... organs after death. ,He observed that for ...
... States will be oganised by the Union Health and Family ... agenda is to come out with a plan to combat ... in India. Chikungunya has taken several lives, predominantly in Kerala. ... of the Health Ministers of the four southern States, Gujarat, ...
... by her ovaries according to a new report.The study conducted ... women put more time and effort into their appearance when ... and makeup affected at that time of the month a ... other alter as well. ,Study's lead author, UCLA ...
Cached Medicine News:Health News:Lowest Spending growth in US Medicaid 2Health News:Crying Need for Awareness on Organ Donation in India: Sir Peter Morris 2Health News:Women’s Fashion Sense Linked to Her Ovulatio 2
9mm Curved Blades with Sharp Pointed Tips; overall length 90mm; Stainless Steel....
Straight shaft with fine pointed 0.3mm Tips for Grasping Delicate Capsule; In Titanium....
Smooth colibri tip; In Titanium....
45 Degree Angle With 0.3, 12 Teeth with 5mm Tying Platform; In Titanium....
Medicine Products: